# Dr. David Sinclair: The First Human Trial of an Age-Reversal Therapy

Page: https://stenobird.com/podcast/the-james-altucher-show-745332/dr-david-sinclair-the-first-human-trial-of-an-age-reversal-therapy
Text version: https://stenobird.com/podcast/the-james-altucher-show-745332/dr-david-sinclair-the-first-human-trial-of-an-age-reversal-therapy.md
Podcast: [The James Altucher Show](https://stenobird.com/podcast/the-james-altucher-show-745332)
Published: 2026-07-03T07:00:00+00:00
Episode link: https://art19.com/shows/the-james-altucher-pod/episodes/d4bb0b42-b709-4463-abed-06001c034a5d
Audio file: https://dts.podtrac.com/redirect.mp3/prfx.byspotify.com/e/claritaspod.com/measure/arttrk.com/p/PDPN1/pscrb.fm/rss/p/rss.art19.com/episodes/d4bb0b42-b709-4463-abed-06001c034a5d.mp3?rss_browser=BAhJIg90cmFuc2NyaWJyBjoGRVQ%3D--952c5701c84ad333c69d5faa668f8177091704f0
Processing state: not_requested
JSON: https://stenobird.com/v1/public/podcasts/the-james-altucher-show-745332/episodes/dr-david-sinclair-the-first-human-trial-of-an-age-reversal-therapy
Duration seconds: 2940

## Resource

A Note from James: I’ve been obsessed with anti-aging and longevity science for a long time. I’ve had many longevity researchers on the podcast, but this episode feels different because something we’ve been discussing for years has now moved into human trials. David Sinclair first came on the show in 2019, when his book Lifespan was published. He’s a professor of genetics at Harvard Medical School, and that first conversation changed how I lived. I started experimenting with intermittent fasting, paid much more attention to sleep, and began researching many of the supplements and lifestyle changes he discussed. But the most important idea David talked about wasn’t a supplement. It was the possibility of reversing cellular age using Yamanaka factors—genes that can reset the instructions cells use to function. At the time, nobody knew whether this could be done safely without causing cancer or making cells lose their identities. Now, a therapy based on three of those factors has entered its first human clinical trial. The initial target is age-related damage to the optic nerve, including open-angle glaucoma and non-arteritic anterior ischemic optic neuropathy. The trial is designed primarily to evaluate safety, but researchers will also measure visual function. David explains how this technology worked in mice and nonhuman primates, why the eye was chosen as the first organ, and how the same approach might eventually be applied to the liver, lungs, joints, skin, and brain. We also cover the practical questions people always ask him: NMN, NAD, metformin, berberine, testosterone, growth hormone, diet, fasting, sleep, exercise, and what David himself has started—or stopped—taking. This is still experimental science. Nobody yet knows whether the animal results will translate…

## Actions

- request_transcript: `POST https://stenobird.com/v1/public/podcasts/the-james-altucher-show-745332/episodes/dr-david-sinclair-the-first-human-trial-of-an-age-reversal-therapy/transcription-requests` — Idempotently request low-priority transcript generation for this episode.
- read_markdown: `GET https://stenobird.com/podcast/the-james-altucher-show-745332/dr-david-sinclair-the-first-human-trial-of-an-age-reversal-therapy.md` — Read the agent-friendly Markdown representation of this episode resource.

A page view does not enqueue transcription. Agents should invoke `request_transcript` explicitly when they need this episode processed.

## Transcript

Full transcripts are not published on public pages unless there is a clear rights basis.